When.com Web Search

  1. Ads

    related to: infusion for osteoporosis recovery time

Search results

  1. Results From The WOW.Com Content Network
  2. Romosozumab - Wikipedia

    en.wikipedia.org/wiki/Romosozumab

    Romosozumab, sold under the brand name Evenity (/ ɪ ˈ v ɛ n ɪ t i / ih-VENN-ih-tee or with the pin-pen merger, / ɪ ˈ v ɪ n ɪ t i / ih-VINN-ih-tee), is a medication used to treat osteoporosis. [7] [8] It has been found to decrease the risk of fractures of the spine. [7] Common side effects include headache, joint pain, and injection site ...

  3. Zoledronic acid - Wikipedia

    en.wikipedia.org/wiki/Zoledronic_acid

    Zoledronic acid is indicated for the prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumor-induced hypercalcemia) in people with advanced malignancies involving bone; the treatment of adults with tumor-induced hypercalcemia (TIH).

  4. Bisphosphonate - Wikipedia

    en.wikipedia.org/wiki/Bisphosphonate

    In large studies, women taking bisphosphonates for osteoporosis have had unusual fractures ("bisphosphonate fractures") in the femur (thigh bone) in the shaft (diaphysis or sub-trochanteric region) of the bone, rather than at the femoral neck, which is the most common site of fracture. However, these fractures are rare (12 in 14,195 women ...

  5. Discovery and development of bisphosphonates - Wikipedia

    en.wikipedia.org/wiki/Discovery_and_development...

    The difference lies in the non-hydrolysable carbon-phosphorus bond of the bisphosphonates which prevents their metabolism and at the same time ensure an effective absorption from the gastrointestinal tract. [9] The primary inhibiting action of the first generation of bisphosphonates on osteoclasts is by inducing apoptosis. The mechanism of ...

  6. Denosumab - Wikipedia

    en.wikipedia.org/wiki/Denosumab

    In June 2010, denosumab was approved by the FDA for use in postmenopausal women with risk of osteoporosis [37] under the brand name Prolia, [38] and in November 2010, as Xgeva for the prevention of skeleton-related events in people with bone metastases from solid tumors. [39] Denosumab is the first RANKL inhibitor to be approved by the FDA. [37]

  7. Gold just saw its biggest yearly gain since 2010 — here's why ...

    www.aol.com/finance/gold-just-saw-biggest-yearly...

    Wall Street analysts expect gold's rally to keep going in 2025 after the precious metal saw its biggest annual jump in 14 years. On Thursday, gold futures jumped more than 1% to hover above $2,670 ...

  1. Ad

    related to: infusion for osteoporosis recovery time